Neos Therapeutics (NEOS) Short Interest Ratio & Short Volume

Short interest is the volume of Neos Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 26th, traders have sold 1,170,000 shares of NEOS short. 2.38% of Neos Therapeutics' shares are currently sold short. Learn More on Neos Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.38% of Neos Therapeutics' floating shares are currently sold short.

Neos Therapeutics saw a drop in short interest in the month of February. As of February 26th, there was short interest totaling 1,170,000 shares, a drop of 9.3% from the previous total of 1,290,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Neos Therapeutics currently has issued a total of 49,757,000 shares. Some of Neos Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Neos Therapeutics currently has a public float of 49,220,000 shares.

2.38% of Neos Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Neos Therapeutics: Procaps Group S.A. (0.12%), OptiNose, Inc. (1.68%), PyroGenesis Canada Inc. (0.14%), Aadi Bioscience, Inc. (6.58%), Actinium Pharmaceuticals, Inc. (4.54%), Eagle Pharmaceuticals, Inc. (0.46%), Marinus Pharmaceuticals, Inc. (3.95%), Allakos Inc. (0.37%), Cara Therapeutics, Inc. (1.74%), NanoViricides, Inc. (1.62%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon plc ($5.72 billion), Analog Devices, Inc. ($5.42 billion), Charter Communications, Inc. ($4.94 billion), Snap Inc. ($3.85 billion), Airbnb, Inc. ($2.46 billion), Warner Bros. Discovery, Inc. ($2.34 billion), Futu Holdings Limited Sponsored ADR ($2.31 billion), The Kroger Co. ($2.05 billion), Peloton Interactive, Inc. ($1.96 billion), and Palo Alto Networks, Inc. ($1.89 billion). View all of the most shorted stocks.

Short selling NEOS is an investing strategy that aims to generate trading profit from Neos Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Neos Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NEOS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NEOS, twice per month. The most recent reporting period available is February, 26 2021.